Alsmeirat Odeh, Lakhani Som, Egaimi Musab, Idris Osama, Elkhalifa Mohamed
Internal Medicine, Sheikh Khalifa Specialty Hospital, Ras Al Khaimah, ARE.
Dermatology, Parul University, Vadodara, IND.
Cureus. 2022 Aug 2;14(8):e27622. doi: 10.7759/cureus.27622. eCollection 2022 Aug.
Facial seborrheic dermatitis (SD) is a chronic inflammatory skin condition that can affect the quality of life with frequent recurrences. There is no medication as yet to cure this disease completely. There are four general categories of agents that are used to treat SD: antifungal agents, keratolytics, corticosteroids, and lastly calcineurin inhibitors. Topical therapies are the mainstream line of treatment to be used for this skin condition. The objective of this article is to critically review the published data in the literature on the use of topical pimecrolimus 1% topical cream as an option for treating facial SD. The final purpose of this review is to answer two questions: whether pimecrolimus topical cream is effective for the treatment of SD compared to the conventional current treatments and how safe is this treatment. The PubMed, Clinicaltrials.gov, MEDLINE + Embase, and Cochrane library databases were searched for original randomized clinical trials (RCTs) evaluating pimecrolimus 1% topical cream and comparing it with other topical treatments for SD. A systematic review and meta-analysis were then conducted on the selected studies by grading the evidence and qualitative comparison of results among and within studies. A total of five studies were included in the review; however, only four were eligible for inclusion in the meta-analysis, in which pimecrolimus was compared with other treatments for the management of facial SD. Pimecrolimus was found to be an effective topical treatment for facial SD, as it showed considerable desirable control of the symptoms in patients with facial SD clinically, in addition to a lower recurrence or relapsing rates; however, it had more side effects compared to other topical treatments, but the side effects were mild and tolerable.
面部脂溢性皮炎（SD）是一种慢性炎症性皮肤病，频繁复发会影响生活质量。目前尚无药物能完全治愈这种疾病。用于治疗SD的药物大致有四类：抗真菌药、角质剥脱剂、皮质类固醇，最后是钙调神经磷酸酶抑制剂。局部治疗是这种皮肤病的主流治疗方法。本文的目的是批判性地回顾文献中已发表的关于使用1%吡美莫司乳膏治疗面部SD的数据。这篇综述的最终目的是回答两个问题：与传统的现有治疗方法相比，吡美莫司乳膏治疗SD是否有效，以及这种治疗的安全性如何。在PubMed、Clinicaltrials.gov、MEDLINE + Embase和Cochrane图书馆数据库中检索评估1%吡美莫司乳膏并将其与其他治疗SD的局部药物进行比较的原始随机临床试验（RCT）。然后对所选研究进行系统评价和荟萃分析，对证据进行分级，并对研究间和研究内的结果进行定性比较。该综述共纳入五项研究；然而，只有四项符合纳入荟萃分析的条件，其中将吡美莫司与其他治疗面部SD的方法进行了比较。结果发现，吡美莫司是治疗面部SD的一种有效局部药物，因为它在临床上能显著控制面部SD患者的症状，此外复发率或复发率较低；然而，与其他局部治疗相比，它有更多的副作用，但副作用轻微且可耐受。
